Evidence map›Paper›PMID 42481711›Full record

Trial reportNature cancer2026

Dalpiciclib plus endocrine therapy in women with HR

Hongnan Mo, Yuee Teng, Li Cai, Huihui Li, Xinhong Wu, Jing Yao, Yu Wang, Dan Lv, Xuenan Peng, Shuchun Wang and 8 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hongnan Mo *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0002-2887-7985
Yuee Teng *The First Hospital of China Medical University, Shenyang, China.
Li Cai *HarBin Medical University Cancer Hospital, HarBin, China.
Huihui Li *Cancer Hospital of Shandong First Medical University, Jinan, China.
Xinhong WuHubei Cancer Hospital, Wuhan, China.
Jing YaoUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu WangShanxi Cancer Hospital, Taiyuan, China.
Dan LvNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xuenan PengNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuchun WangBeijing Geneplus Technology Co., Ltd, Beijing, China.ORCID http://orcid.org/0009-0003-8797-3568
Rongrong ChenBeijing Geneplus Technology Co., Ltd, Beijing, China.
Xin YiBeijing Geneplus Technology Co., Ltd, Beijing, China.
Qingyao ShangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Youwen HeDuke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0002-8983-2684
Ji LiuJiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Zheng PangJiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Tianyu FengJiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Fei MaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. drmafei@126.com.ORCID http://orcid.org/0000-0001-9432-1902

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral crisis in advanced breast cancer (ABC) represents a major challenge. Here we conducted a phase 2 study to evaluate dalpiciclib plus endocrine therapy (ET) in women with HR

Indexed as

Antineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedFemaleHumansMiddle AgedPiperidinesPyridinesPyrimidinesReceptors, EstrogenReceptors, ProgesteroneAntineoplastic Agents, HormonaldalpiciclibERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPiperidinesPyridinesPyrimidinesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID42481711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.